MEpedia - User contributions [en]

Charles Lapp

2019-08-27T07:40:11Z

EHMARNP:/* References */ Date of Retirement correction

[[File:Dr. Charles Lapp.png|right|Source: Hunter-Hopkins Center]]
'''Charles W. Lapp''', MD, is a retired Internal Medicine physician and the Medical Director Emeritus at [[Hunter-Hopkins Center]] in Charlotte, North Carolina, [[United States|US]], which has a practice specializing in [[ME/CFS]], [[FM]], and related conditions. Earlier in his career, he practiced family medicine and pediatrics in Raleigh, NC.<ref name=":1">{{Cite web|url=https://drlapp.com/news/me-letter-february-2018/#retires|title=ME Letter February 2018|language=en-US|access-date=2018-12-23|date=|website=|last=|first=|authorlink=|last2=|first2=|authorlink2=|archive-url=|archive-date=|dead-url=}}</ref> He became interested in [[ME/CFS]] following an outbreak of three small epidemics of a chronic fatiguing illness in the Raleigh area. [[1984 Chapel Hill outbreak|One of these outbreaks]] was among all the members of the N.C. Symphony Orchestra.<ref>{{Cite web|url=http://newsok.com/article/3366622|title=Cause of illness remains unknown|last=Garloch|first=Karen|date=2009|website=NewsOK|archive-url=|archive-date=|dead-url=|access-date=|authorlink=|last2=|first2=|authorlink2=}}</ref>

From 1992 to 1995 Dr. Lapp acted as Medical Director of the Cheney Clinic in Charlotte, in collaboration with Dr. [[Paul Cheney]]. In August 1995, Dr. Lapp opened the Hunter-Hopkins Center in Charlotte, North Carolina where he practiced until his retirement in 2018.<ref name=":1" /> His center does testing for disability insurance such as the 2-day [[Cardiopulmonary exercise testing]] ([[CPET]]) and a computer-assisted cognitive function test.

Following Dr. Lapp's retirement in 2018, the Hunter-Hopkins Center director became Dr. [[Vincent Hillman|Vincent F. Hillman]] with Dr. [[Laura Black]] continuing on staff.<ref name=":1" />

==Awards==

*2009, Nelson Gantz Outstanding Clinician Award awarded to a physician who emulates Nelson Gantz's clinical acumen, his passion for medicine, and his empathy for persons with CFS/FM awarded by [[International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis|IACFS/ME.]]<ref>{{Cite web|url=http://iacfsme.org/Organization/Former-IACFS-ME-Awardees.aspx|title=Former IACFS/ME Awardees|last=International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis|first=|authorlink=International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis|last2=|first2=|authorlink2=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref>

==IOM Committee on Diagnostic Criteria for ME/CFS==
Dr Lapp was a reviewer for the [[Institute of Medicine report|2015 report]] produced by the [[Institute of Medicine]]'s Committee on Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.<ref>{{Cite web|url=https://www.nap.edu/resource/19012/MECFS_Powerpoint.pdf|title=ME/CFS Presentation|last=Institute of Medicine|first=|authorlink=Institute of Medicine|last2=|first2=|authorlink2=|date=|website=www.nap.edu|archive-url=|archive-date=|dead-url=|access-date=2018-12-23}}</ref>

==Pediatric Case Definition==

*2006, A [[Pediatric]] Case Definition for [[Myalgic Encephalomyelitis]] and [[Chronic Fatigue Syndrome]]<ref name="JasonL2006paed" /> [https://solvecfs.org/wp-content/uploads/2013/06/pediatriccasedefinitionshort.pdf (Full Text)]

==Clinical Trials==
The [[Hunter-Hopkins Center]] was one of two clinical sites participating in the [[Hemispherx Biopharma]] 511/open label [[Ampligen]] trials to gain [[FDA]] approval, which was ultimately unsuccessful. The [[Ampligen]] phase III trial results were published in 2012.<ref name="Strayer, 2012" /><ref name=":0">{{Cite web|url=https://drlapp.com/research/#tabs_6431815605c1f658582e55-tab_2|title=Ampligen {{!}} Research {{!}} Hunter-Hopkins Center, P.A.|last=Hunter-Hopkins Center|first=|authorlink=Hunter-Hopkins Center|last2=|first2=|authorlink2=|date=|website=|language=en-US|archive-url=|archive-date=|dead-url=|access-date=2018-12-23}}</ref> Ampligen, a brand name for '''Rintatolimod''', is an IV medication, and was given twice weekly at the Hunter-Hopkins infusion room during the trial. The Hunter-Hopkins Center is currently one of four clinics that can administer Ampligen in the US.<ref name=":0" />

==Clinic location==

:Hunter-Hopkins Center
:7421 Carmel Executive Park Dr.
:Charlotte, North Carolina 28226
:Telephone: (704) 543-9692
:Email: drlapp@drlapp.net

==Notable Studies==

*1997, Management of Chronic Fatigue Syndrome in Children: A Practicing Clinician's Approach<ref>Charles W. Lapp. (1997). Management of Chronic Fatigue Syndrome in Children: A Practicing Clinician's Approach. ''Journal of Chronic Fatigue Syndrome,'' Vol. 3, Iss. 2, pp 59-76. http://dx.doi.org/10.1300/J092v03n02_07</ref>
*1998, Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome.<ref name="Vojdani, 1998" />
*1999, The Relationship Between Chronic Fatigue Syndrome and Chemical Exposure<ref>Aristo Vojdani & Charles W. Lapp. (1999). The Relationship Between Chronic Fatigue Syndrome and Chemical Exposure. ''Journal of Chronic Fatigue Syndrome'', Vol. 5, Iss. 3-4, pp. 207-221. http://dx.doi.org/10.1300/J092v05n03_18</ref>
*2006, Recognizing Pediatric CFS in the Primary Care Practice: A Practicing Clinician's Approach<ref>Charles W. Lapp. (2006). Recognizing Pediatric CFS in the Primary Care Practice: A Practicing Clinician's Approach. ''Journal of Chronic Fatigue Syndrome'', Vol. 13, Iss. 2-3, pp. 89-96. http://dx.doi.org/10.1300/J092v13n02_06</ref>
*2007, Defining the Occurrence and Influence of Alpha-Delta Sleep in [[Chronic Fatigue Syndrome]]<ref name="Van Hoof, 2007" /> [https://www.ncbi.nlm.nih.gov/pubmed/17301585 (Abstract)]
*2009, Severe versus Moderate criteria for the new [[pediatric]] case definition for [[ME/CFS]]<ref name="Jason, Dec2009" /> [https://www.ncbi.nlm.nih.gov/pubmed/19513826 (Abstract)]
*2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist [[rintatolimod]] in severe cases of chronic fatigue syndrome<ref name="Strayer, 2012" /> [http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0031334 (Full Text)]
*2014, No association found between the detection of either [[xenotropic murine leukemia virus-related virus]] or polytropic murine leukemia virus and [[chronic fatigue syndrome]] in a blinded, multi-site, prospective study by the establishment and use of the [[SolveCFS BioBank & Patient Registry|SolveCFS BioBank]]<ref>{{Cite journal|last=Irlbeck|first=David M.|last2=Vernon|first2=Suzanne D.|author-link2=Suzanne Vernon|last3=McCleary|first3=K. Kimberly|author-link3=Kim McCleary|last4=Bateman|first4=Lucinda|author-link4=Lucinda Bateman|last5=Klimas|first5=Nancy G.|author-link5=Nancy Klimas|last6=Lapp|first6=Charles W.|author-link6=Charles Lapp|last7=Peterson|first7=Daniel L.|author-link7=Daniel Peterson|last8=Brown|first8=James R.|last9=Remlinger|first9=Katja S.|date=2014|title=No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236736/|journal=BMC Research Notes|volume=7|pages=461|doi=10.1186/1756-0500-7-461|via=|last10=Wilfret|last11=Gerondelis|first11=Peter|first10=David A.}}</ref> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236736/ (Full Text)]
*2016, [[CDC]] Grand Rounds: [[Chronic Fatigue Syndrome]] — Advancing Research and Clinical Education. Morbidity and [[Mortality]] Weekly Report<ref>{{Cite journal|last1=Unger|first1=ER|authorlink1=Elizabeth Unger|last2=Lin|first2=JS|authorlink2=Jin-Mann Sally Lin|last3=Brimmer|first3=DJ|authorlink3=|last4=Lapp|first4=CW|authorlink4=Charles Lapp|last5=Komaroff|first5=AL|authorlink5=Anthony Komaroff|last6=Nath|first6=A|authorlink6=Avindra Nath|last7=Laird|first7=S|authorlink7=| last8=Iskander|first8=J|authorlink8=John Iskander|title=CDC Grand Rounds: Chronic Fatigue Syndrome — Advancing Research and Clinical Education|journal=Morbidity and Mortality Weekly Report|volume=65|issue=5051|page=1434–1438|date=2016|doi=10.15585/mmwr.mm655051a4}} - </ref> - [https://www.cdc.gov/mmwr/volumes/65/wr/mm655051a4.htm (Full Text)]
*2017, Multi-Site Clinical Assessment of [[ME/CFS|Myalgic Encephalomyelitis/Chronic Fatigue Syndrome]] (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study<ref name="Unger, 2017" /> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565838/ (Full Text)]
*2019, Initiating care of a patient with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)<ref>{{Cite journal|last=Lapp|first=Charles W.|author-link=Charles Lapp|author-link2=|author-link3=|author-link4=|author-link5=|date=Jan 2019|title=Initiating Care Of A Patient With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS)|url=https://www.frontiersin.org/articles/10.3389/fped.2018.00415/abstract|journal=Frontiers in Pediatrics|volume=|issue=|pages=|doi=10.3389/fped.2018.00415|quote=|via=}}</ref> [https://www.frontiersin.org/articles/10.3389/fped.2018.00415/full (Full text)]
*2019, Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning<ref>{{Cite journal|last=Proskauer|first=Charmian|author-link=Charmian Proskauer|last2=Rowe|first2=Peter C.|author-link2=Peter Rowe|last3=Lapp|first3=Charles W.|author-link3=Charles Lapp|last4=DeMaria|first4=Alfred Jr|author-link4=|last5=Bateman|first5=Lucinda|author-link5=Lucinda Bateman|last6=Attewell|first6=John R.|last7=Proskauer|first7=Daniel|last8=Kiernicki|first8=David J.|last9=Adebayo|first9=Seyi|date=2019|title=Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning|url=https://www.frontiersin.org/articles/10.3389/fped.2018.00412/full|journal=Frontiers in Pediatrics|language=English|volume=6|issue=|pages=|doi=10.3389/fped.2018.00412|issn=2296-2360|pmc=|pmid=30671425|quote=|via=}}</ref> [https://www.frontiersin.org/articles/10.3389/fped.2018.00412/full (Full text)]

==Talks & interviews==

*[http://www.cfidsselfhelp.org/library/dr-lapp's-recommedations-supplements Dr. Lapp’s recommendations on supplements]<ref>{{Cite web|url=http://www.cfidsselfhelp.org/library/dr-lapp%27s-recommedations-supplements|title=Dr Lapp's Recommendations on Supplements {{!}} ME/CFS & Fibromyalgia Self-Help|last=Campbell|first=Bruce|authorlink=Bruce Campbell|last2=|first2=|authorlink2=|date=|website=www.cfidsselfhelp.org|archive-url=|archive-date=|dead-url=|access-date=2018-12-23}}</ref>
*16 Feb 2016, CDC Grand Rounds - Chronic Fatigue Syndrome: Advancing Research and Clinical Education with Charles Lapp, MD, [[Elizabeth Unger]], PhD, MD, [[Anthony Komaroff]], MD and [[Avindra Nath]], MD

::[https://www.cdc.gov/grand-rounds/pp/2016/20160216-chronic-fatigue.html Grand Rounds Video]
::[https://www.cdc.gov/grand-rounds/pp/2016/20160216-presentation-chronic-fatigue-H.pdf Grand Rounds Presentation Slide Deck]

*17 Apr 2017, [https://www.youtube.com/watch?v=RTzfWs6Fhl4 Dr Charles Lapp - An overview of ME/CFS Diagnosis and Management]

==HHS/CFSAC Testimony==

*[http://www.hhs.gov/advcomcfs/meetings/presentations/cortjohnson.pdf Oct 29, 2009 Testimony (read by] [[Cort Johnson]])

==Open Letter to ''The Lancet''==
Three open letters to the editor of ''The Lancet'' urged the editor to commission a fully independent review of the [[PACE trial]], which the journal had published in 2011. In 2016, Dr. Lapp, along with 42 colleagues in the [[ME/CFS]] field, signed the second letter.<ref>{{Cite web|url=http://www.virology.ws/2016/02/10/open-letter-lancet-again/|title=Open Letter Lancet Again|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref> In 2018, Dr. Lapp, with more than 100 colleagues in the [[ME/CFS]] field, signed the third letter.<ref>{{Cite web|url=http://www.virology.ws/2018/06/19/trial-by-error-an-open-letter-to-the-lancet-two-years-on/|title=An Open Letter to The Lancet, Two Years On|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref>

*10 February 2016, [http://www.virology.ws/2016/02/10/open-letter-lancet-again/ An open letter to The Lancet, again - Virology blog]
*18 June 2018, [http://www.virology.ws/2018/06/19/trial-by-error-an-open-letter-to-the-lancet-two-years-on/ Trial By Error: An Open Letter to The Lancet, Two Years On]

==Online presence==

*[https://www.ncbi.nlm.nih.gov/pubmed/?term=Lapp%20CW%5BAuthor%5D&cauthor=true&cauthor_uid=25092471 PubMed - Charles Lapp]
*[https://www.facebook.com/HunterHopkinsCenterFans/?filter=2 Hunter-Hopkins Center Facebook page]
*[http://drlapp.com/ Hunter-Hopkins Center website]

==Learn more==

*2012, [http://drlapp.com/ask-the-doctor/what-are-the-most-important-things-to-remember-about-cfs-fm/ What Are The Most Important Things To Remember About CFS/FM?]
*[http://drlapp.com/staff/curriculum-vitae-charles-w-lapp-md/ Curriculum Vitae - Charles W. Lapp, MD]
*2018, [https://www.healthrising.org/blog/2018/03/28/lapp-chronic-fatigue-syndrome-fibromyalgia-pioneer-retires/ An ME/CFS and FM Pioneer Says Good-bye: The Charles Lapp Interview]<ref>{{Cite web|url=https://www.healthrising.org/blog/2018/03/28/lapp-chronic-fatigue-syndrome-fibromyalgia-pioneer-retires/|title=An ME/CFS and FM Pioneer Says Good-bye: The Charles Lapp Interview|last=Johnson|first=Cort|authorlink=Cort Johnson|last2=|first2=|authorlink2=|date=2018-03-28|website=[[Health Rising]]|language=en-GB|archive-url=|archive-date=|dead-url=|access-date=2018-12-23}}</ref>

==See also==

*[[NIH Post-Infectious ME/CFS Study]]
*[[Ampligen]]
*[[1984 Chapel Hill outbreak]]
*Dr. [[Laura Black]]

==References==
<references>
<ref name="Jason, Dec2009">{{Citation
| last1 = Jason | first1 = Leonard | authorlink1 = Leonard Jason
| last2 = Porter | first2 = Nicole | authorlink2 = Nicole Porter
| last3 = Shelleby | first3 = E | authorlink3 =
| last4 = Till | first4 = L | authorlink4 =
| last5 = Bell | first5 = David S | authorlink5 = David Bell
| last6 = Lapp | first6 = Charles W | authorlink6 = Charles Lapp
| last7 = Rowe | first7 = Kathy | authorlink7 = Kathy Rowe
| last8 = De Meirleir | first8 = Kenny | authorlink8 = Kenny De Meirleir
| title = Severe versus Moderate criteria for the new pediatric case definition for ME/CFS
| journal = Child Psychiatry and Human Development | volume = 40 | issue = 4 | page = 609-20
| date = 2009
| pmid =
| doi = 10.1007/s10578-009-0147-8
}}
</ref>
<ref name="JasonL2006paed">{{citation
| last1 = Jason | first1 = Leonard A | authorlink1 = Leonard Jason
| last2 = Jordan | first2 = Karen | authorlink2 = Karen Jordan
| last3 = Miike | first3 = Teruhisa | authorlink3 = Teruhisa Miike
| last4 = Bell | first4 = David S | authorlink4 = David Bell
| last5 = Lapp | first5 = Charles | authorlink5 = Charles Lapp
| last6 = Torres-Harding | first6 = Susan | authorlink6 = Susan Torres-Harding
| last7 = Rowe | first7 = Kathy | authorlink7 = Kathy Rowe
| last8 = Gurwitt | first8 = Alan | authorlink8 = Alan Gurwitt
| last9 = De Meirleir | first9 = Kenny | authorlink9 = Kenny de Meirleir
| last10 = Van Hoof | first10= Elke LS | authorlink10= Elke Van Hoof
| title = A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome
| journal = Journal of Chronic Fatigue Syndrome | volume = 13 | issue = 2-3 | page = 1-44
| date = 2006
| doi = 10.1300/J092v13n02_01
| url = https://solvecfs.org/wp-content/uploads/2013/06/pediatriccasedefinitionshort.pdf
}}</ref>
<ref name="Strayer, 2012">{{Citation
| last1 = Strayer | first1 = DR | authorlink1 = David Strayer
| last2 = Carter | first2 = WA | authorlink2 = William Carter
| last3 = Stouch | first3 = BC | authorlink3 =
| last4 = Stevens | first4 = SR | authorlink4 = Staci Stevens
| last5 = Bateman | first5 = L | authorlink5 = Lucinda Bateman
| last6 = Cimoch | first6 = PJ | authorlink6 =
| last7 = Lapp | first7 = CW | authorlink7 = Charles Lapp
| last8 = Peterson | first8 = DL | authorlink8 = Daniel Peterson
| last9 = Chronic Fatigue Syndrome AMP-516 Study Group | authorlink9 =
| last10 = Mitchell | first10 = WM | authorlink10 = William Mitchell
| title = A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.
| journal = PLoS One | volume = 7 | issue = 3 | page = e31334
| date = 2012
| pmid = 22431963
| doi = 10.1371/journal.pone.0031334
}}
</ref>
<ref name="Unger, 2017">{{Citation
| last1 = Unger | first1 = Elizabeth R. | authorlink1 = Elizabeth Unger
| last2 = Lin | first2 = Jin-Mann S. | authorlink2 = Jin-Mann Sally Lin
| last3 = Tian | first3 = Hao | authorlink3 =
| last4 = Natelson | first4 = Benjamin H. | authorlink4 = Benjamin Natelson
| last5 = Lange | first5 = Gudrun | authorlink5 = Gudrun Lange
| last6 = Vu | first6 = Diana | authorlink6 =
| last7 = Blate | first7 = Michelle | authorlink7 =
| last8 = Klimas | first8 = Nancy G. | authorlink8 = Nancy Klimas
| last9 = Balbin | first9 = Elizabeth G. | authorlink9 =
| last10 = Bateman | first10 = Lucinda | authorlink10 = Lucinda Bateman
| last11 = Allen | first11 = Ali | authorlink11 =
| last12 = Lapp | first12 = Charles W. | authorlink12 = Charles Lapp
| last13 = Springs | first13 = Wendy | authorlink13 =
| last14 = Kogelnik | first14 = Andreas M. | authorlink14 = Andreas Kogelnik
| last15 = Phan | first15 = Catrina C. | authorlink15 =
| last16 = Danver | first16 = Joan | authorlink16 =
| last17 = Podell | first17 = Richard N. | authorlink17 = Richard Podell
| last18 = Fitzpatrick | first18 = Trisha | authorlink18 =
| last19 = Peterson | first19 = Daniel L. | authorlink19 = Daniel Peterson
| last20 = Gottschalk | first20 = C. Gunnar | authorlink20 = Gunnar Gottschalk
| last21 = Rajeevan | first21 = Mangalathu S.| authorlink21 = Mangalathu Rajeevan
| last22 = MCAM Study Group
| title = Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study.
| journal = American Journal of Epidemiology | volume = 1-10 | issue = | page =
| date = 2017
| pmid =
| doi = 10.1093/aje/kwx029
}}
</ref>
<ref name="Van Hoof, 2007">{{Citation
| last1 = Van Hoof | first1 = E | authorlink1 = Elke Van Hoof
| last2 = De Becker | first2 = P | authorlink2 = Pascale De Becker
| last3 = Lapp | first3 = C | authorlink3 = Charles Lapp
| last4 = Cluydts | first4 = R | authorlink4 =
| last5 = De Meirleir | first5 = K | authorlink5 = Kenny de Meirleir
| title = Defining the Occurrence and Influence of Alpha-Delta Sleep in Chronic Fatigue Syndrome
| journal = The American Journal of the Medical Sciences | volume = 333 | issue = 2 | page = 78-84
| date = 2007
| pmid = 17301585
| doi =
}}
</ref>
<ref name="Vojdani, 1998">{{Citation
| last1 = Vojdani | first1 = A | authorlink1 =
| last2 = Choppa | first2 = PC | authorlink2 =
| last3 = Lapp | first3 = CW | authorlink3 = Charles Lapp
| title = Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome
| journal = J Clin Lab Immunol | volume = 50 | issue = 1 | page = 1-16
| date = 1998
| pmid = 10189612
| doi =
}}
</ref>
</references>

[[Category:Researchers]]
[[Category:US researchers]]
[[Category:Clinicians]]
[[Category:American clinicians]]
[[Category:North Carolina clinicians]]
[[Category:Psychological paradigm critics]]
[[Category:PACE trial critics]]
[[Category:CFSAC members]]

Charles Lapp

2019-08-27T07:29:57Z

EHMARNP:Year of retirement was 2018. (Dr. Lapp retired the end of Feb/beginning of March 2018, not 2017 as previously recorded)

[[File:Dr. Charles Lapp.png|right|Source: Hunter-Hopkins Center]]
'''Charles W. Lapp''', MD, is a retired Internal Medicine physician and the Medical Director Emeritus at [[Hunter-Hopkins Center]] in Charlotte, North Carolina, [[United States|US]], which has a practice specializing in [[ME/CFS]], [[FM]], and related conditions. Earlier in his career, he practiced family medicine and pediatrics in Raleigh, NC.<ref name=":1">{{Cite web|url=https://drlapp.com/staff/|title=Staff {{!}} Hunter-Hopkins Center, P.A.|language=en-US|access-date=2018-12-23}}</ref> He became interested in [[ME/CFS]] following an outbreak of three small epidemics of a chronic fatiguing illness in the Raleigh area. [[1984 Chapel Hill outbreak|One of these outbreaks]] was among all the members of the N.C. Symphony Orchestra.<ref>{{Cite web|url=http://newsok.com/article/3366622|title=Cause of illness remains unknown|last=Garloch|first=Karen|date=2009|website=NewsOK|archive-url=|archive-date=|dead-url=|access-date=|authorlink=|last2=|first2=|authorlink2=}}</ref>

From 1992 to 1995 Dr. Lapp acted as Medical Director of the Cheney Clinic in Charlotte, in collaboration with Dr. [[Paul Cheney]]. In August 1995, Dr. Lapp opened the Hunter-Hopkins Center in Charlotte, North Carolina where he practiced until his retirement in 2018.<ref name=":1" /> His center does testing for disability insurance such as the 2-day [[Cardiopulmonary exercise testing]] ([[CPET]]) and a computer-assisted cognitive function test.

Following Dr. Lapp's retirement in 2018, the Hunter-Hopkins Center director became Dr. [[Vincent Hillman|Vincent F. Hillman]] with Dr. [[Laura Black]] continuing on staff.<ref name=":1" />

==Awards==

*2009, Nelson Gantz Outstanding Clinician Award awarded to a physician who emulates Nelson Gantz's clinical acumen, his passion for medicine, and his empathy for persons with CFS/FM awarded by [[International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis|IACFS/ME.]]<ref>{{Cite web|url=http://iacfsme.org/Organization/Former-IACFS-ME-Awardees.aspx|title=Former IACFS/ME Awardees|last=International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis|first=|authorlink=International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis|last2=|first2=|authorlink2=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref>

==IOM Committee on Diagnostic Criteria for ME/CFS==
Dr Lapp was a reviewer for the [[Institute of Medicine report|2015 report]] produced by the [[Institute of Medicine]]'s Committee on Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.<ref>{{Cite web|url=https://www.nap.edu/resource/19012/MECFS_Powerpoint.pdf|title=ME/CFS Presentation|last=Institute of Medicine|first=|authorlink=Institute of Medicine|last2=|first2=|authorlink2=|date=|website=www.nap.edu|archive-url=|archive-date=|dead-url=|access-date=2018-12-23}}</ref>

==Pediatric Case Definition==

*2006, A [[Pediatric]] Case Definition for [[Myalgic Encephalomyelitis]] and [[Chronic Fatigue Syndrome]]<ref name="JasonL2006paed" /> [https://solvecfs.org/wp-content/uploads/2013/06/pediatriccasedefinitionshort.pdf (Full Text)]

==Clinical Trials==
The [[Hunter-Hopkins Center]] was one of two clinical sites participating in the [[Hemispherx Biopharma]] 511/open label [[Ampligen]] trials to gain [[FDA]] approval, which was ultimately unsuccessful. The [[Ampligen]] phase III trial results were published in 2012.<ref name="Strayer, 2012" /><ref name=":0">{{Cite web|url=https://drlapp.com/research/#tabs_6431815605c1f658582e55-tab_2|title=Ampligen {{!}} Research {{!}} Hunter-Hopkins Center, P.A.|last=Hunter-Hopkins Center|first=|authorlink=Hunter-Hopkins Center|last2=|first2=|authorlink2=|date=|website=|language=en-US|archive-url=|archive-date=|dead-url=|access-date=2018-12-23}}</ref> Ampligen, a brand name for '''Rintatolimod''', is an IV medication, and was given twice weekly at the Hunter-Hopkins infusion room during the trial. The Hunter-Hopkins Center is currently one of four clinics that can administer Ampligen in the US.<ref name=":0" />

==Clinic location==

:Hunter-Hopkins Center
:7421 Carmel Executive Park Dr.
:Charlotte, North Carolina 28226
:Telephone: (704) 543-9692
:Email: drlapp@drlapp.net

==Notable Studies==

*1997, Management of Chronic Fatigue Syndrome in Children: A Practicing Clinician's Approach<ref>Charles W. Lapp. (1997). Management of Chronic Fatigue Syndrome in Children: A Practicing Clinician's Approach. ''Journal of Chronic Fatigue Syndrome,'' Vol. 3, Iss. 2, pp 59-76. http://dx.doi.org/10.1300/J092v03n02_07</ref>
*1998, Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome.<ref name="Vojdani, 1998" />
*1999, The Relationship Between Chronic Fatigue Syndrome and Chemical Exposure<ref>Aristo Vojdani & Charles W. Lapp. (1999). The Relationship Between Chronic Fatigue Syndrome and Chemical Exposure. ''Journal of Chronic Fatigue Syndrome'', Vol. 5, Iss. 3-4, pp. 207-221. http://dx.doi.org/10.1300/J092v05n03_18</ref>
*2006, Recognizing Pediatric CFS in the Primary Care Practice: A Practicing Clinician's Approach<ref>Charles W. Lapp. (2006). Recognizing Pediatric CFS in the Primary Care Practice: A Practicing Clinician's Approach. ''Journal of Chronic Fatigue Syndrome'', Vol. 13, Iss. 2-3, pp. 89-96. http://dx.doi.org/10.1300/J092v13n02_06</ref>
*2007, Defining the Occurrence and Influence of Alpha-Delta Sleep in [[Chronic Fatigue Syndrome]]<ref name="Van Hoof, 2007" /> [https://www.ncbi.nlm.nih.gov/pubmed/17301585 (Abstract)]
*2009, Severe versus Moderate criteria for the new [[pediatric]] case definition for [[ME/CFS]]<ref name="Jason, Dec2009" /> [https://www.ncbi.nlm.nih.gov/pubmed/19513826 (Abstract)]
*2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist [[rintatolimod]] in severe cases of chronic fatigue syndrome<ref name="Strayer, 2012" /> [http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0031334 (Full Text)]
*2014, No association found between the detection of either [[xenotropic murine leukemia virus-related virus]] or polytropic murine leukemia virus and [[chronic fatigue syndrome]] in a blinded, multi-site, prospective study by the establishment and use of the [[SolveCFS BioBank & Patient Registry|SolveCFS BioBank]]<ref>{{Cite journal|last=Irlbeck|first=David M.|last2=Vernon|first2=Suzanne D.|author-link2=Suzanne Vernon|last3=McCleary|first3=K. Kimberly|author-link3=Kim McCleary|last4=Bateman|first4=Lucinda|author-link4=Lucinda Bateman|last5=Klimas|first5=Nancy G.|author-link5=Nancy Klimas|last6=Lapp|first6=Charles W.|author-link6=Charles Lapp|last7=Peterson|first7=Daniel L.|author-link7=Daniel Peterson|last8=Brown|first8=James R.|last9=Remlinger|first9=Katja S.|date=2014|title=No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236736/|journal=BMC Research Notes|volume=7|pages=461|doi=10.1186/1756-0500-7-461|via=|last10=Wilfret|last11=Gerondelis|first11=Peter|first10=David A.}}</ref> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236736/ (Full Text)]
*2016, [[CDC]] Grand Rounds: [[Chronic Fatigue Syndrome]] — Advancing Research and Clinical Education. Morbidity and [[Mortality]] Weekly Report<ref>{{Cite journal|last1=Unger|first1=ER|authorlink1=Elizabeth Unger|last2=Lin|first2=JS|authorlink2=Jin-Mann Sally Lin|last3=Brimmer|first3=DJ|authorlink3=|last4=Lapp|first4=CW|authorlink4=Charles Lapp|last5=Komaroff|first5=AL|authorlink5=Anthony Komaroff|last6=Nath|first6=A|authorlink6=Avindra Nath|last7=Laird|first7=S|authorlink7=| last8=Iskander|first8=J|authorlink8=John Iskander|title=CDC Grand Rounds: Chronic Fatigue Syndrome — Advancing Research and Clinical Education|journal=Morbidity and Mortality Weekly Report|volume=65|issue=5051|page=1434–1438|date=2016|doi=10.15585/mmwr.mm655051a4}} - </ref> - [https://www.cdc.gov/mmwr/volumes/65/wr/mm655051a4.htm (Full Text)]
*2017, Multi-Site Clinical Assessment of [[ME/CFS|Myalgic Encephalomyelitis/Chronic Fatigue Syndrome]] (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study<ref name="Unger, 2017" /> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565838/ (Full Text)]
*2019, Initiating care of a patient with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)<ref>{{Cite journal|last=Lapp|first=Charles W.|author-link=Charles Lapp|author-link2=|author-link3=|author-link4=|author-link5=|date=Jan 2019|title=Initiating Care Of A Patient With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS)|url=https://www.frontiersin.org/articles/10.3389/fped.2018.00415/abstract|journal=Frontiers in Pediatrics|volume=|issue=|pages=|doi=10.3389/fped.2018.00415|quote=|via=}}</ref> [https://www.frontiersin.org/articles/10.3389/fped.2018.00415/full (Full text)]
*2019, Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning<ref>{{Cite journal|last=Proskauer|first=Charmian|author-link=Charmian Proskauer|last2=Rowe|first2=Peter C.|author-link2=Peter Rowe|last3=Lapp|first3=Charles W.|author-link3=Charles Lapp|last4=DeMaria|first4=Alfred Jr|author-link4=|last5=Bateman|first5=Lucinda|author-link5=Lucinda Bateman|last6=Attewell|first6=John R.|last7=Proskauer|first7=Daniel|last8=Kiernicki|first8=David J.|last9=Adebayo|first9=Seyi|date=2019|title=Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning|url=https://www.frontiersin.org/articles/10.3389/fped.2018.00412/full|journal=Frontiers in Pediatrics|language=English|volume=6|issue=|pages=|doi=10.3389/fped.2018.00412|issn=2296-2360|pmc=|pmid=30671425|quote=|via=}}</ref> [https://www.frontiersin.org/articles/10.3389/fped.2018.00412/full (Full text)]

==Talks & interviews==

*[http://www.cfidsselfhelp.org/library/dr-lapp's-recommedations-supplements Dr. Lapp’s recommendations on supplements]<ref>{{Cite web|url=http://www.cfidsselfhelp.org/library/dr-lapp%27s-recommedations-supplements|title=Dr Lapp's Recommendations on Supplements {{!}} ME/CFS & Fibromyalgia Self-Help|last=Campbell|first=Bruce|authorlink=Bruce Campbell|last2=|first2=|authorlink2=|date=|website=www.cfidsselfhelp.org|archive-url=|archive-date=|dead-url=|access-date=2018-12-23}}</ref>
*16 Feb 2016, CDC Grand Rounds - Chronic Fatigue Syndrome: Advancing Research and Clinical Education with Charles Lapp, MD, [[Elizabeth Unger]], PhD, MD, [[Anthony Komaroff]], MD and [[Avindra Nath]], MD

::[https://www.cdc.gov/grand-rounds/pp/2016/20160216-chronic-fatigue.html Grand Rounds Video]
::[https://www.cdc.gov/grand-rounds/pp/2016/20160216-presentation-chronic-fatigue-H.pdf Grand Rounds Presentation Slide Deck]

*17 Apr 2017, [https://www.youtube.com/watch?v=RTzfWs6Fhl4 Dr Charles Lapp - An overview of ME/CFS Diagnosis and Management]

==HHS/CFSAC Testimony==

*[http://www.hhs.gov/advcomcfs/meetings/presentations/cortjohnson.pdf Oct 29, 2009 Testimony (read by] [[Cort Johnson]])

==Open Letter to ''The Lancet''==
Three open letters to the editor of ''The Lancet'' urged the editor to commission a fully independent review of the [[PACE trial]], which the journal had published in 2011. In 2016, Dr. Lapp, along with 42 colleagues in the [[ME/CFS]] field, signed the second letter.<ref>{{Cite web|url=http://www.virology.ws/2016/02/10/open-letter-lancet-again/|title=Open Letter Lancet Again|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref> In 2018, Dr. Lapp, with more than 100 colleagues in the [[ME/CFS]] field, signed the third letter.<ref>{{Cite web|url=http://www.virology.ws/2018/06/19/trial-by-error-an-open-letter-to-the-lancet-two-years-on/|title=An Open Letter to The Lancet, Two Years On|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref>

*10 February 2016, [http://www.virology.ws/2016/02/10/open-letter-lancet-again/ An open letter to The Lancet, again - Virology blog]
*18 June 2018, [http://www.virology.ws/2018/06/19/trial-by-error-an-open-letter-to-the-lancet-two-years-on/ Trial By Error: An Open Letter to The Lancet, Two Years On]

==Online presence==

*[https://www.ncbi.nlm.nih.gov/pubmed/?term=Lapp%20CW%5BAuthor%5D&cauthor=true&cauthor_uid=25092471 PubMed - Charles Lapp]
*[https://www.facebook.com/HunterHopkinsCenterFans/?filter=2 Hunter-Hopkins Center Facebook page]
*[http://drlapp.com/ Hunter-Hopkins Center website]

==Learn more==

*2012, [http://drlapp.com/ask-the-doctor/what-are-the-most-important-things-to-remember-about-cfs-fm/ What Are The Most Important Things To Remember About CFS/FM?]
*[http://drlapp.com/staff/curriculum-vitae-charles-w-lapp-md/ Curriculum Vitae - Charles W. Lapp, MD]
*2018, [https://www.healthrising.org/blog/2018/03/28/lapp-chronic-fatigue-syndrome-fibromyalgia-pioneer-retires/ An ME/CFS and FM Pioneer Says Good-bye: The Charles Lapp Interview]<ref>{{Cite web|url=https://www.healthrising.org/blog/2018/03/28/lapp-chronic-fatigue-syndrome-fibromyalgia-pioneer-retires/|title=An ME/CFS and FM Pioneer Says Good-bye: The Charles Lapp Interview|last=Johnson|first=Cort|authorlink=Cort Johnson|last2=|first2=|authorlink2=|date=2018-03-28|website=[[Health Rising]]|language=en-GB|archive-url=|archive-date=|dead-url=|access-date=2018-12-23}}</ref>

==See also==

*[[NIH Post-Infectious ME/CFS Study]]
*[[Ampligen]]
*[[1984 Chapel Hill outbreak]]
*Dr. [[Laura Black]]

==References==
<references>
<ref name="Jason, Dec2009">{{Citation
| last1 = Jason | first1 = Leonard | authorlink1 = Leonard Jason
| last2 = Porter | first2 = Nicole | authorlink2 = Nicole Porter
| last3 = Shelleby | first3 = E | authorlink3 =
| last4 = Till | first4 = L | authorlink4 =
| last5 = Bell | first5 = David S | authorlink5 = David Bell
| last6 = Lapp | first6 = Charles W | authorlink6 = Charles Lapp
| last7 = Rowe | first7 = Kathy | authorlink7 = Kathy Rowe
| last8 = De Meirleir | first8 = Kenny | authorlink8 = Kenny De Meirleir
| title = Severe versus Moderate criteria for the new pediatric case definition for ME/CFS
| journal = Child Psychiatry and Human Development | volume = 40 | issue = 4 | page = 609-20
| date = 2009
| pmid =
| doi = 10.1007/s10578-009-0147-8
}}
</ref>
<ref name="JasonL2006paed">{{citation
| last1 = Jason | first1 = Leonard A | authorlink1 = Leonard Jason
| last2 = Jordan | first2 = Karen | authorlink2 = Karen Jordan
| last3 = Miike | first3 = Teruhisa | authorlink3 = Teruhisa Miike
| last4 = Bell | first4 = David S | authorlink4 = David Bell
| last5 = Lapp | first5 = Charles | authorlink5 = Charles Lapp
| last6 = Torres-Harding | first6 = Susan | authorlink6 = Susan Torres-Harding
| last7 = Rowe | first7 = Kathy | authorlink7 = Kathy Rowe
| last8 = Gurwitt | first8 = Alan | authorlink8 = Alan Gurwitt
| last9 = De Meirleir | first9 = Kenny | authorlink9 = Kenny de Meirleir
| last10 = Van Hoof | first10= Elke LS | authorlink10= Elke Van Hoof
| title = A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome
| journal = Journal of Chronic Fatigue Syndrome | volume = 13 | issue = 2-3 | page = 1-44
| date = 2006
| doi = 10.1300/J092v13n02_01
| url = https://solvecfs.org/wp-content/uploads/2013/06/pediatriccasedefinitionshort.pdf
}}</ref>
<ref name="Strayer, 2012">{{Citation
| last1 = Strayer | first1 = DR | authorlink1 = David Strayer
| last2 = Carter | first2 = WA | authorlink2 = William Carter
| last3 = Stouch | first3 = BC | authorlink3 =
| last4 = Stevens | first4 = SR | authorlink4 = Staci Stevens
| last5 = Bateman | first5 = L | authorlink5 = Lucinda Bateman
| last6 = Cimoch | first6 = PJ | authorlink6 =
| last7 = Lapp | first7 = CW | authorlink7 = Charles Lapp
| last8 = Peterson | first8 = DL | authorlink8 = Daniel Peterson
| last9 = Chronic Fatigue Syndrome AMP-516 Study Group | authorlink9 =
| last10 = Mitchell | first10 = WM | authorlink10 = William Mitchell
| title = A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.
| journal = PLoS One | volume = 7 | issue = 3 | page = e31334
| date = 2012
| pmid = 22431963
| doi = 10.1371/journal.pone.0031334
}}
</ref>
<ref name="Unger, 2017">{{Citation
| last1 = Unger | first1 = Elizabeth R. | authorlink1 = Elizabeth Unger
| last2 = Lin | first2 = Jin-Mann S. | authorlink2 = Jin-Mann Sally Lin
| last3 = Tian | first3 = Hao | authorlink3 =
| last4 = Natelson | first4 = Benjamin H. | authorlink4 = Benjamin Natelson
| last5 = Lange | first5 = Gudrun | authorlink5 = Gudrun Lange
| last6 = Vu | first6 = Diana | authorlink6 =
| last7 = Blate | first7 = Michelle | authorlink7 =
| last8 = Klimas | first8 = Nancy G. | authorlink8 = Nancy Klimas
| last9 = Balbin | first9 = Elizabeth G. | authorlink9 =
| last10 = Bateman | first10 = Lucinda | authorlink10 = Lucinda Bateman
| last11 = Allen | first11 = Ali | authorlink11 =
| last12 = Lapp | first12 = Charles W. | authorlink12 = Charles Lapp
| last13 = Springs | first13 = Wendy | authorlink13 =
| last14 = Kogelnik | first14 = Andreas M. | authorlink14 = Andreas Kogelnik
| last15 = Phan | first15 = Catrina C. | authorlink15 =
| last16 = Danver | first16 = Joan | authorlink16 =
| last17 = Podell | first17 = Richard N. | authorlink17 = Richard Podell
| last18 = Fitzpatrick | first18 = Trisha | authorlink18 =
| last19 = Peterson | first19 = Daniel L. | authorlink19 = Daniel Peterson
| last20 = Gottschalk | first20 = C. Gunnar | authorlink20 = Gunnar Gottschalk
| last21 = Rajeevan | first21 = Mangalathu S.| authorlink21 = Mangalathu Rajeevan
| last22 = MCAM Study Group
| title = Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study.
| journal = American Journal of Epidemiology | volume = 1-10 | issue = | page =
| date = 2017
| pmid =
| doi = 10.1093/aje/kwx029
}}
</ref>
<ref name="Van Hoof, 2007">{{Citation
| last1 = Van Hoof | first1 = E | authorlink1 = Elke Van Hoof
| last2 = De Becker | first2 = P | authorlink2 = Pascale De Becker
| last3 = Lapp | first3 = C | authorlink3 = Charles Lapp
| last4 = Cluydts | first4 = R | authorlink4 =
| last5 = De Meirleir | first5 = K | authorlink5 = Kenny de Meirleir
| title = Defining the Occurrence and Influence of Alpha-Delta Sleep in Chronic Fatigue Syndrome
| journal = The American Journal of the Medical Sciences | volume = 333 | issue = 2 | page = 78-84
| date = 2007
| pmid = 17301585
| doi =
}}
</ref>
<ref name="Vojdani, 1998">{{Citation
| last1 = Vojdani | first1 = A | authorlink1 =
| last2 = Choppa | first2 = PC | authorlink2 =
| last3 = Lapp | first3 = CW | authorlink3 = Charles Lapp
| title = Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome
| journal = J Clin Lab Immunol | volume = 50 | issue = 1 | page = 1-16
| date = 1998
| pmid = 10189612
| doi =
}}
</ref>
</references>

[[Category:Researchers]]
[[Category:US researchers]]
[[Category:Clinicians]]
[[Category:American clinicians]]
[[Category:North Carolina clinicians]]
[[Category:Psychological paradigm critics]]
[[Category:PACE trial critics]]
[[Category:CFSAC members]]

Charles Lapp

2019-08-27T07:25:56Z

EHMARNP:Date of retirement was off by 1 year. Dr. Lapp retired in 2018. I saw him as a pt in Feb 2018; he was retiring at the end of that month.

[[File:Dr. Charles Lapp.png|right|Source: Hunter-Hopkins Center]]
'''Charles W. Lapp''', MD, is a retired Internal Medicine physician and the Medical Director Emeritus at [[Hunter-Hopkins Center]] in Charlotte, North Carolina, [[United States|US]], which has a practice specializing in [[ME/CFS]], [[FM]], and related conditions. Earlier in his career, he practiced family medicine and pediatrics in Raleigh, NC.<ref name=":1">{{Cite web|url=https://drlapp.com/staff/|title=Staff {{!}} Hunter-Hopkins Center, P.A.|language=en-US|access-date=2018-12-23}}</ref> He became interested in [[ME/CFS]] following an outbreak of three small epidemics of a chronic fatiguing illness in the Raleigh area. [[1984 Chapel Hill outbreak|One of these outbreaks]] was among all the members of the N.C. Symphony Orchestra.<ref>{{Cite web|url=http://newsok.com/article/3366622|title=Cause of illness remains unknown|last=Garloch|first=Karen|date=2009|website=NewsOK|archive-url=|archive-date=|dead-url=|access-date=|authorlink=|last2=|first2=|authorlink2=}}</ref>

From 1992 to 1995 Dr. Lapp acted as Medical Director of the Cheney Clinic in Charlotte, in collaboration with Dr. [[Paul Cheney]]. In August 1995, Dr. Lapp opened the Hunter-Hopkins Center in Charlotte, North Carolina where he practiced until his retirement in 2018.<ref name=":1" /> His center does testing for disability insurance such as the 2-day [[Cardiopulmonary exercise testing]] ([[CPET]]) and a computer-assisted cognitive function test.

Following Dr. Lapp's retirement in 2017, the Hunter-Hopkins Center director became Dr. [[Vincent Hillman|Vincent F. Hillman]] with Dr. [[Laura Black]] continuing on staff.<ref name=":1" />

==Awards==

*2009, Nelson Gantz Outstanding Clinician Award awarded to a physician who emulates Nelson Gantz's clinical acumen, his passion for medicine, and his empathy for persons with CFS/FM awarded by [[International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis|IACFS/ME.]]<ref>{{Cite web|url=http://iacfsme.org/Organization/Former-IACFS-ME-Awardees.aspx|title=Former IACFS/ME Awardees|last=International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis|first=|authorlink=International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis|last2=|first2=|authorlink2=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref>

==IOM Committee on Diagnostic Criteria for ME/CFS==
Dr Lapp was a reviewer for the [[Institute of Medicine report|2015 report]] produced by the [[Institute of Medicine]]'s Committee on Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.<ref>{{Cite web|url=https://www.nap.edu/resource/19012/MECFS_Powerpoint.pdf|title=ME/CFS Presentation|last=Institute of Medicine|first=|authorlink=Institute of Medicine|last2=|first2=|authorlink2=|date=|website=www.nap.edu|archive-url=|archive-date=|dead-url=|access-date=2018-12-23}}</ref>

==Pediatric Case Definition==

*2006, A [[Pediatric]] Case Definition for [[Myalgic Encephalomyelitis]] and [[Chronic Fatigue Syndrome]]<ref name="JasonL2006paed" /> [https://solvecfs.org/wp-content/uploads/2013/06/pediatriccasedefinitionshort.pdf (Full Text)]

==Clinical Trials==
The [[Hunter-Hopkins Center]] was one of two clinical sites participating in the [[Hemispherx Biopharma]] 511/open label [[Ampligen]] trials to gain [[FDA]] approval, which was ultimately unsuccessful. The [[Ampligen]] phase III trial results were published in 2012.<ref name="Strayer, 2012" /><ref name=":0">{{Cite web|url=https://drlapp.com/research/#tabs_6431815605c1f658582e55-tab_2|title=Ampligen {{!}} Research {{!}} Hunter-Hopkins Center, P.A.|last=Hunter-Hopkins Center|first=|authorlink=Hunter-Hopkins Center|last2=|first2=|authorlink2=|date=|website=|language=en-US|archive-url=|archive-date=|dead-url=|access-date=2018-12-23}}</ref> Ampligen, a brand name for '''Rintatolimod''', is an IV medication, and was given twice weekly at the Hunter-Hopkins infusion room during the trial. The Hunter-Hopkins Center is currently one of four clinics that can administer Ampligen in the US.<ref name=":0" />

==Clinic location==

:Hunter-Hopkins Center
:7421 Carmel Executive Park Dr.
:Charlotte, North Carolina 28226
:Telephone: (704) 543-9692
:Email: drlapp@drlapp.net

==Notable Studies==

*1997, Management of Chronic Fatigue Syndrome in Children: A Practicing Clinician's Approach<ref>Charles W. Lapp. (1997). Management of Chronic Fatigue Syndrome in Children: A Practicing Clinician's Approach. ''Journal of Chronic Fatigue Syndrome,'' Vol. 3, Iss. 2, pp 59-76. http://dx.doi.org/10.1300/J092v03n02_07</ref>
*1998, Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome.<ref name="Vojdani, 1998" />
*1999, The Relationship Between Chronic Fatigue Syndrome and Chemical Exposure<ref>Aristo Vojdani & Charles W. Lapp. (1999). The Relationship Between Chronic Fatigue Syndrome and Chemical Exposure. ''Journal of Chronic Fatigue Syndrome'', Vol. 5, Iss. 3-4, pp. 207-221. http://dx.doi.org/10.1300/J092v05n03_18</ref>
*2006, Recognizing Pediatric CFS in the Primary Care Practice: A Practicing Clinician's Approach<ref>Charles W. Lapp. (2006). Recognizing Pediatric CFS in the Primary Care Practice: A Practicing Clinician's Approach. ''Journal of Chronic Fatigue Syndrome'', Vol. 13, Iss. 2-3, pp. 89-96. http://dx.doi.org/10.1300/J092v13n02_06</ref>
*2007, Defining the Occurrence and Influence of Alpha-Delta Sleep in [[Chronic Fatigue Syndrome]]<ref name="Van Hoof, 2007" /> [https://www.ncbi.nlm.nih.gov/pubmed/17301585 (Abstract)]
*2009, Severe versus Moderate criteria for the new [[pediatric]] case definition for [[ME/CFS]]<ref name="Jason, Dec2009" /> [https://www.ncbi.nlm.nih.gov/pubmed/19513826 (Abstract)]
*2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist [[rintatolimod]] in severe cases of chronic fatigue syndrome<ref name="Strayer, 2012" /> [http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0031334 (Full Text)]
*2014, No association found between the detection of either [[xenotropic murine leukemia virus-related virus]] or polytropic murine leukemia virus and [[chronic fatigue syndrome]] in a blinded, multi-site, prospective study by the establishment and use of the [[SolveCFS BioBank & Patient Registry|SolveCFS BioBank]]<ref>{{Cite journal|last=Irlbeck|first=David M.|last2=Vernon|first2=Suzanne D.|author-link2=Suzanne Vernon|last3=McCleary|first3=K. Kimberly|author-link3=Kim McCleary|last4=Bateman|first4=Lucinda|author-link4=Lucinda Bateman|last5=Klimas|first5=Nancy G.|author-link5=Nancy Klimas|last6=Lapp|first6=Charles W.|author-link6=Charles Lapp|last7=Peterson|first7=Daniel L.|author-link7=Daniel Peterson|last8=Brown|first8=James R.|last9=Remlinger|first9=Katja S.|date=2014|title=No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236736/|journal=BMC Research Notes|volume=7|pages=461|doi=10.1186/1756-0500-7-461|via=|last10=Wilfret|last11=Gerondelis|first11=Peter|first10=David A.}}</ref> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236736/ (Full Text)]
*2016, [[CDC]] Grand Rounds: [[Chronic Fatigue Syndrome]] — Advancing Research and Clinical Education. Morbidity and [[Mortality]] Weekly Report<ref>{{Cite journal|last1=Unger|first1=ER|authorlink1=Elizabeth Unger|last2=Lin|first2=JS|authorlink2=Jin-Mann Sally Lin|last3=Brimmer|first3=DJ|authorlink3=|last4=Lapp|first4=CW|authorlink4=Charles Lapp|last5=Komaroff|first5=AL|authorlink5=Anthony Komaroff|last6=Nath|first6=A|authorlink6=Avindra Nath|last7=Laird|first7=S|authorlink7=| last8=Iskander|first8=J|authorlink8=John Iskander|title=CDC Grand Rounds: Chronic Fatigue Syndrome — Advancing Research and Clinical Education|journal=Morbidity and Mortality Weekly Report|volume=65|issue=5051|page=1434–1438|date=2016|doi=10.15585/mmwr.mm655051a4}} - </ref> - [https://www.cdc.gov/mmwr/volumes/65/wr/mm655051a4.htm (Full Text)]
*2017, Multi-Site Clinical Assessment of [[ME/CFS|Myalgic Encephalomyelitis/Chronic Fatigue Syndrome]] (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study<ref name="Unger, 2017" /> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565838/ (Full Text)]
*2019, Initiating care of a patient with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)<ref>{{Cite journal|last=Lapp|first=Charles W.|author-link=Charles Lapp|author-link2=|author-link3=|author-link4=|author-link5=|date=Jan 2019|title=Initiating Care Of A Patient With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS)|url=https://www.frontiersin.org/articles/10.3389/fped.2018.00415/abstract|journal=Frontiers in Pediatrics|volume=|issue=|pages=|doi=10.3389/fped.2018.00415|quote=|via=}}</ref> [https://www.frontiersin.org/articles/10.3389/fped.2018.00415/full (Full text)]
*2019, Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning<ref>{{Cite journal|last=Proskauer|first=Charmian|author-link=Charmian Proskauer|last2=Rowe|first2=Peter C.|author-link2=Peter Rowe|last3=Lapp|first3=Charles W.|author-link3=Charles Lapp|last4=DeMaria|first4=Alfred Jr|author-link4=|last5=Bateman|first5=Lucinda|author-link5=Lucinda Bateman|last6=Attewell|first6=John R.|last7=Proskauer|first7=Daniel|last8=Kiernicki|first8=David J.|last9=Adebayo|first9=Seyi|date=2019|title=Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning|url=https://www.frontiersin.org/articles/10.3389/fped.2018.00412/full|journal=Frontiers in Pediatrics|language=English|volume=6|issue=|pages=|doi=10.3389/fped.2018.00412|issn=2296-2360|pmc=|pmid=30671425|quote=|via=}}</ref> [https://www.frontiersin.org/articles/10.3389/fped.2018.00412/full (Full text)]

==Talks & interviews==

*[http://www.cfidsselfhelp.org/library/dr-lapp's-recommedations-supplements Dr. Lapp’s recommendations on supplements]<ref>{{Cite web|url=http://www.cfidsselfhelp.org/library/dr-lapp%27s-recommedations-supplements|title=Dr Lapp's Recommendations on Supplements {{!}} ME/CFS & Fibromyalgia Self-Help|last=Campbell|first=Bruce|authorlink=Bruce Campbell|last2=|first2=|authorlink2=|date=|website=www.cfidsselfhelp.org|archive-url=|archive-date=|dead-url=|access-date=2018-12-23}}</ref>
*16 Feb 2016, CDC Grand Rounds - Chronic Fatigue Syndrome: Advancing Research and Clinical Education with Charles Lapp, MD, [[Elizabeth Unger]], PhD, MD, [[Anthony Komaroff]], MD and [[Avindra Nath]], MD

::[https://www.cdc.gov/grand-rounds/pp/2016/20160216-chronic-fatigue.html Grand Rounds Video]
::[https://www.cdc.gov/grand-rounds/pp/2016/20160216-presentation-chronic-fatigue-H.pdf Grand Rounds Presentation Slide Deck]

*17 Apr 2017, [https://www.youtube.com/watch?v=RTzfWs6Fhl4 Dr Charles Lapp - An overview of ME/CFS Diagnosis and Management]

==HHS/CFSAC Testimony==

*[http://www.hhs.gov/advcomcfs/meetings/presentations/cortjohnson.pdf Oct 29, 2009 Testimony (read by] [[Cort Johnson]])

==Open Letter to ''The Lancet''==
Three open letters to the editor of ''The Lancet'' urged the editor to commission a fully independent review of the [[PACE trial]], which the journal had published in 2011. In 2016, Dr. Lapp, along with 42 colleagues in the [[ME/CFS]] field, signed the second letter.<ref>{{Cite web|url=http://www.virology.ws/2016/02/10/open-letter-lancet-again/|title=Open Letter Lancet Again|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref> In 2018, Dr. Lapp, with more than 100 colleagues in the [[ME/CFS]] field, signed the third letter.<ref>{{Cite web|url=http://www.virology.ws/2018/06/19/trial-by-error-an-open-letter-to-the-lancet-two-years-on/|title=An Open Letter to The Lancet, Two Years On|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref>

*10 February 2016, [http://www.virology.ws/2016/02/10/open-letter-lancet-again/ An open letter to The Lancet, again - Virology blog]
*18 June 2018, [http://www.virology.ws/2018/06/19/trial-by-error-an-open-letter-to-the-lancet-two-years-on/ Trial By Error: An Open Letter to The Lancet, Two Years On]

==Online presence==

*[https://www.ncbi.nlm.nih.gov/pubmed/?term=Lapp%20CW%5BAuthor%5D&cauthor=true&cauthor_uid=25092471 PubMed - Charles Lapp]
*[https://www.facebook.com/HunterHopkinsCenterFans/?filter=2 Hunter-Hopkins Center Facebook page]
*[http://drlapp.com/ Hunter-Hopkins Center website]

==Learn more==

*2012, [http://drlapp.com/ask-the-doctor/what-are-the-most-important-things-to-remember-about-cfs-fm/ What Are The Most Important Things To Remember About CFS/FM?]
*[http://drlapp.com/staff/curriculum-vitae-charles-w-lapp-md/ Curriculum Vitae - Charles W. Lapp, MD]
*2018, [https://www.healthrising.org/blog/2018/03/28/lapp-chronic-fatigue-syndrome-fibromyalgia-pioneer-retires/ An ME/CFS and FM Pioneer Says Good-bye: The Charles Lapp Interview]<ref>{{Cite web|url=https://www.healthrising.org/blog/2018/03/28/lapp-chronic-fatigue-syndrome-fibromyalgia-pioneer-retires/|title=An ME/CFS and FM Pioneer Says Good-bye: The Charles Lapp Interview|last=Johnson|first=Cort|authorlink=Cort Johnson|last2=|first2=|authorlink2=|date=2018-03-28|website=[[Health Rising]]|language=en-GB|archive-url=|archive-date=|dead-url=|access-date=2018-12-23}}</ref>

==See also==

*[[NIH Post-Infectious ME/CFS Study]]
*[[Ampligen]]
*[[1984 Chapel Hill outbreak]]
*Dr. [[Laura Black]]

==References==
<references>
<ref name="Jason, Dec2009">{{Citation
| last1 = Jason | first1 = Leonard | authorlink1 = Leonard Jason
| last2 = Porter | first2 = Nicole | authorlink2 = Nicole Porter
| last3 = Shelleby | first3 = E | authorlink3 =
| last4 = Till | first4 = L | authorlink4 =
| last5 = Bell | first5 = David S | authorlink5 = David Bell
| last6 = Lapp | first6 = Charles W | authorlink6 = Charles Lapp
| last7 = Rowe | first7 = Kathy | authorlink7 = Kathy Rowe
| last8 = De Meirleir | first8 = Kenny | authorlink8 = Kenny De Meirleir
| title = Severe versus Moderate criteria for the new pediatric case definition for ME/CFS
| journal = Child Psychiatry and Human Development | volume = 40 | issue = 4 | page = 609-20
| date = 2009
| pmid =
| doi = 10.1007/s10578-009-0147-8
}}
</ref>
<ref name="JasonL2006paed">{{citation
| last1 = Jason | first1 = Leonard A | authorlink1 = Leonard Jason
| last2 = Jordan | first2 = Karen | authorlink2 = Karen Jordan
| last3 = Miike | first3 = Teruhisa | authorlink3 = Teruhisa Miike
| last4 = Bell | first4 = David S | authorlink4 = David Bell
| last5 = Lapp | first5 = Charles | authorlink5 = Charles Lapp
| last6 = Torres-Harding | first6 = Susan | authorlink6 = Susan Torres-Harding
| last7 = Rowe | first7 = Kathy | authorlink7 = Kathy Rowe
| last8 = Gurwitt | first8 = Alan | authorlink8 = Alan Gurwitt
| last9 = De Meirleir | first9 = Kenny | authorlink9 = Kenny de Meirleir
| last10 = Van Hoof | first10= Elke LS | authorlink10= Elke Van Hoof
| title = A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome
| journal = Journal of Chronic Fatigue Syndrome | volume = 13 | issue = 2-3 | page = 1-44
| date = 2006
| doi = 10.1300/J092v13n02_01
| url = https://solvecfs.org/wp-content/uploads/2013/06/pediatriccasedefinitionshort.pdf
}}</ref>
<ref name="Strayer, 2012">{{Citation
| last1 = Strayer | first1 = DR | authorlink1 = David Strayer
| last2 = Carter | first2 = WA | authorlink2 = William Carter
| last3 = Stouch | first3 = BC | authorlink3 =
| last4 = Stevens | first4 = SR | authorlink4 = Staci Stevens
| last5 = Bateman | first5 = L | authorlink5 = Lucinda Bateman
| last6 = Cimoch | first6 = PJ | authorlink6 =
| last7 = Lapp | first7 = CW | authorlink7 = Charles Lapp
| last8 = Peterson | first8 = DL | authorlink8 = Daniel Peterson
| last9 = Chronic Fatigue Syndrome AMP-516 Study Group | authorlink9 =
| last10 = Mitchell | first10 = WM | authorlink10 = William Mitchell
| title = A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.
| journal = PLoS One | volume = 7 | issue = 3 | page = e31334
| date = 2012
| pmid = 22431963
| doi = 10.1371/journal.pone.0031334
}}
</ref>
<ref name="Unger, 2017">{{Citation
| last1 = Unger | first1 = Elizabeth R. | authorlink1 = Elizabeth Unger
| last2 = Lin | first2 = Jin-Mann S. | authorlink2 = Jin-Mann Sally Lin
| last3 = Tian | first3 = Hao | authorlink3 =
| last4 = Natelson | first4 = Benjamin H. | authorlink4 = Benjamin Natelson
| last5 = Lange | first5 = Gudrun | authorlink5 = Gudrun Lange
| last6 = Vu | first6 = Diana | authorlink6 =
| last7 = Blate | first7 = Michelle | authorlink7 =
| last8 = Klimas | first8 = Nancy G. | authorlink8 = Nancy Klimas
| last9 = Balbin | first9 = Elizabeth G. | authorlink9 =
| last10 = Bateman | first10 = Lucinda | authorlink10 = Lucinda Bateman
| last11 = Allen | first11 = Ali | authorlink11 =
| last12 = Lapp | first12 = Charles W. | authorlink12 = Charles Lapp
| last13 = Springs | first13 = Wendy | authorlink13 =
| last14 = Kogelnik | first14 = Andreas M. | authorlink14 = Andreas Kogelnik
| last15 = Phan | first15 = Catrina C. | authorlink15 =
| last16 = Danver | first16 = Joan | authorlink16 =
| last17 = Podell | first17 = Richard N. | authorlink17 = Richard Podell
| last18 = Fitzpatrick | first18 = Trisha | authorlink18 =
| last19 = Peterson | first19 = Daniel L. | authorlink19 = Daniel Peterson
| last20 = Gottschalk | first20 = C. Gunnar | authorlink20 = Gunnar Gottschalk
| last21 = Rajeevan | first21 = Mangalathu S.| authorlink21 = Mangalathu Rajeevan
| last22 = MCAM Study Group
| title = Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study.
| journal = American Journal of Epidemiology | volume = 1-10 | issue = | page =
| date = 2017
| pmid =
| doi = 10.1093/aje/kwx029
}}
</ref>
<ref name="Van Hoof, 2007">{{Citation
| last1 = Van Hoof | first1 = E | authorlink1 = Elke Van Hoof
| last2 = De Becker | first2 = P | authorlink2 = Pascale De Becker
| last3 = Lapp | first3 = C | authorlink3 = Charles Lapp
| last4 = Cluydts | first4 = R | authorlink4 =
| last5 = De Meirleir | first5 = K | authorlink5 = Kenny de Meirleir
| title = Defining the Occurrence and Influence of Alpha-Delta Sleep in Chronic Fatigue Syndrome
| journal = The American Journal of the Medical Sciences | volume = 333 | issue = 2 | page = 78-84
| date = 2007
| pmid = 17301585
| doi =
}}
</ref>
<ref name="Vojdani, 1998">{{Citation
| last1 = Vojdani | first1 = A | authorlink1 =
| last2 = Choppa | first2 = PC | authorlink2 =
| last3 = Lapp | first3 = CW | authorlink3 = Charles Lapp
| title = Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome
| journal = J Clin Lab Immunol | volume = 50 | issue = 1 | page = 1-16
| date = 1998
| pmid = 10189612
| doi =
}}
</ref>
</references>

[[Category:Researchers]]
[[Category:US researchers]]
[[Category:Clinicians]]
[[Category:American clinicians]]
[[Category:North Carolina clinicians]]
[[Category:Psychological paradigm critics]]
[[Category:PACE trial critics]]
[[Category:CFSAC members]]